ArticleInternational journal of nanomedicine2018
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 36 citations in OpenAlex.
- Development and Evaluation of "a PEGylated Anti-Tau ScFv for SPECT Imaging" in a Rat Model of Traumatic Brain Injury.Pharmaceutics · 2026Article
- Immune cell engagers in lung cancer.Frontiers in immunology · 2026Review
- The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non-Toxic Treatment Option for Superficial Triple Negative Breast Cancer.Cancer medicine · 2025Review
- Nanobodies and their derivatives: pioneering the future of cancer immunotherapy.Cell communication and signaling : CCS · 2025Review
- Enhancing the structural stability of P29-targeted monoclonal antibodies via β-hydroxybutyrylation modification improves their therapeutic performance in alveolar echinococcosis.Frontiers in cellular and infection microbiology · 2025Article
- Nonshrinkable Thermosensitive Hydrogels Combined with Bispecific Anti-PSMA/CD3 T-Cell Engager for Effective Against Tumors in Mice Model.International journal of nanomedicine · 2025Article
- Single-Domain Antibodies as Antibody-Drug Conjugates: From Promise to Practice-A Systematic Review.Cancers · 2024Review
- Review
- 10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer.Frontiers in oncology · 2024Review
- Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment-Drug Conjugates Carrying Maytansinoids DM1 and DM4.Current issues in molecular biology · 2023Article
- Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.Frontiers in immunology · 2023Review
- Screening and identification of an anti-PD-1 nanobody with antitumor activity.Bioscience reports · 2022Article
- Antibody variable region engineering for improving cancer immunotherapy.Cancer communications (London, England) · 2022Review
- The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma.Biomedicines · 2022Review
- Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents.Journal of nanobiotechnology · 2022Article
- Development of anti-membrane type 1-matrix metalloproteinase nanobodies as immunoPET probes for triple negative breast cancer imaging.Frontiers in medicine · 2022Article
- DNA-based delivery of anti-DR5 Nanobodies improves exposure and anti-tumor efficacy over protein-based administration.Cancer gene therapy · 2021Article
- An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010-2020 review.Nanoscale advances · 2021Review
- Universal endogenous antibody recruiting nanobodies capable of triggering immune effectors for targeted cancer immunotherapy.Chemical science · 2021Article
- Nanobody: a promising toolkit for molecular imaging and disease therapy.EJNMMI research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBispecific antibodies that engage immune cells to kill cancer cells are actively pursued in cancer immunotherapy. Different types of bispecific antibodies, including single-chain fragments, Fab fragments, nanobodies, and immunoglobulin Gs (IgGs), have been studied. However, the low molecular weight of bispecific antibodies with single-chain or Fab fragments generally leads to their rapid clearance in vivo, which limits the therapeutic potential of these bispecific antibodies. MATERIALS AND
methodsIn this study, we used a site-specific PEGylation strategy to modify the bispecific single-domain antibody-linked Fab (S-Fab), which was designed by linking an anticarcinoembryonic antigen (anti-CEA) nanobody with an anti-CD3 Fab.
resultsThe half-life (
conclusionThis study demonstrated that PEGylation is an effective approach to enhance the antitumor efficacy of bispecific antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.